Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + lomustine + vincristine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination chemotherapy regimen containing cyclophosphamide (an alkylating agent that damages DNA by causing cross-links), doxorubicin (an anthracycline antibiotic that damages DNA by inserting itself between DNA bases), lomustine (a nitrosourea alkylating agent), and vincristine (a vinca alkaloid that prevents cell division by binding to tubulin). This combination likely works by attacking cancer cells through multiple mechanisms to prevent cell replication and division.

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + lomustine + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + lomustine + vincristine.

Explore the full profile